top of page

Better monitoring of biological medicines

The European Medicines Agency (EMA) has adopted a new chapter to its guidelines ongood pharmacovigilance practices (EU-GVP), entitled “Product- or population-specific considerations II: Biological medicinal products”. Good pharmacovigilance practices are a set of measures designed to ensure the robustness of the system of safety monitoring. The new chapter provides guidance on how to better monitor and manage the safety of biological medicines to optimise the safe and effective use of these products in Europe.

Click on this link for more information.


Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page